Heron Therapeutics to Report Second Quarter 2025 Financial Results on Monday, August 11, 2025
Rhea-AI Summary
Heron Therapeutics (NASDAQ: HRTX), a commercial-stage biotechnology company, has scheduled its second quarter 2025 financial results conference call for Monday, August 11, 2025, at 4:30 p.m. ET. The company will discuss Q2 2025 financial performance and recent business highlights during the call.
Participants can access the conference call through a registration link and are encouraged to dial in fifteen minutes before the scheduled start time. A webcast will be available through Heron's Investor Relations website section, with a 60-day replay period following the call.
Positive
- None.
Negative
- None.
News Market Reaction
On the day this news was published, HRTX declined 0.54%, reflecting a mild negative market reaction.
Data tracked by StockTitan Argus on the day of publication.
The conference call can be accessed by phone by utilizing the following registration link which will provide participants with dial-in details. To avoid delays, we encourage participants to dial into the conference call fifteen minutes ahead of the scheduled start time. The conference call will also be available via webcast under the Investor Relations section of Heron's website at www.herontx.com. An archive of the teleconference and webcast will also be made available on Heron's website for 60 days following the call.
About Heron Therapeutics, Inc.
Heron Therapeutics, Inc. is a commercial-stage biotechnology company focused on improving the lives of patients by developing and commercializing therapeutic innovations that improve medical care. Our advanced science, patented technologies, and innovative approach to drug discovery and development have allowed us to create and commercialize a portfolio of products that aim to advance the standard-of-care for acute care and oncology patients. For more information, visit www.herontx.com.
Forward-looking Statements
This news release contains "forward-looking statements" as defined by the Private Securities Litigation Reform Act of 1995. Heron cautions readers that forward-looking statements are based on management's expectations and assumptions as of the date of this news release and are subject to certain risks and uncertainties that could cause actual results to differ materially. These risks and uncertainties include, but are not limited to, risks and uncertainties identified in the Company's filings with the Securities and Exchange Commission. Forward-looking statements reflect our analysis only on their stated date, and Heron takes no obligation to update or revise these statements except as may be required by law.
Investor Relations and Media Contact:
Ira Duarte
Executive Vice President, Chief Financial Officer
Heron Therapeutics, Inc.
iduarte@herontx.com
858-251-4400
View original content to download multimedia:https://www.prnewswire.com/news-releases/heron-therapeutics-to-report-second-quarter-2025-financial-results-on-monday-august-11-2025-302515450.html
SOURCE Heron Therapeutics, Inc.
FAQ
When will Heron Therapeutics (HRTX) report Q2 2025 earnings?
How can investors access Heron Therapeutics' Q2 2025 earnings call?
How long will Heron Therapeutics' Q2 2025 earnings call replay be available?
What topics will be covered in Heron Therapeutics' Q2 2025 earnings call?
